In 2011 this blog was listed as one of the top 10 blog in pharma technical information it is popular amongst the pharmacists and pharma industry professionals. We have published very important and very useful information for pharma industry professionals.

Monday, July 1, 2013

Type 2 Diabetes : ChREBP-β gene could be new target for new drugs for treatment of Type 2 Diabetes

Type 2 diabetes development linked to higher expression of gene responsible for insulin resistance in fatty tissuse. 

Diabetes is a disease which is developed over the period of time, as glucose present in blood is not mobilized in to body tissue viz, fat cells and muscles. Increase blood glucose level disrupts normal health and lead towards development of subsequent diseases like hyper tension, aging and muscular weakness and so on.

Insulin is a hormone in our body which regulates mobilization of blood glucose in to muscle and fat cells, it act upon muscle and fatty tissue cells , adipose tissue cells and trigger activation of protein molecules called as Glucose transporter type4 GLUT4 which facilitate transportation of glucose in to fat and muscle cells in our body, where glucose is used a source of energy and for tissue building. 

There are following types of diabetes 
 Type 1 Diabetes: Pancreas is not able to produce sufficient amount of Insulin, it may be because of several genetic factors and autoimmune diseases where cells producing insulin in pancreases are destroyed.

Type 2 Diabetes: In this type of diabetes peripheral muscle cells and fat cells produce resistance towards action of insulin or effect of insulin with respect to transportation of glucose is reduced, which is also related to Glucose transporter type 4 GLUT4.

Drs. Barbara Kahn and Mark Herman from Harvard Medical School and Beth Israel Deaconess Medical Center and their team have found that a gene ChREBP-β expressed highly which can be related to insulin resistance.

The high concentration of Glucose transporter type 4 GLUT4 which is responsible for mobilization and fatty tissue building . is related to higher expression of gene responsible ChREBP, and its other form gene ChREBP-β which was found in high level in mice feed with high fat diet, and in adipose tissue of individuals with insulin resistance therefore can be related to development of insulin resistance and obesity.

Higher expression of ChREBP-β is related to insulin resistance in fatty tissue therefore in future it could be one of target for developing a new drug to treat type 2 diabetes.


No comments:


What is 21 CFR Part 11, US FDA guidelines requirements of FDA compliance and CFR 21 Part 11.

What is a Site Master file of a pharmaceutical company

What is Generic Drug

What is Reference Listed Drug  ? ( RLD )

What is Pharmaceutical Equivalents

What is Pharmaceutical Alternatives

What is Therapeutic Equivalents

What are Post Market studies

Why a drug is bound to protein, What is protein binding?  What is drug absorption , distribution ?

Do Physical properties contribute to drug activity.

What is drug receptor , How a drug resistance occurs

Mechanism of drug resistance

What is drug interaction

Drug interaction, and its examples

What is first pass metabolism of a drug

What is What is 510(k) Clearances ?

What is 510(k) Clearances,

Premarket Notification for medical devices - PMN or 510(k)

What is a drug interaction

Examples of drug interactions


Antibiotic Definition and classification


Antibiotic Resistance and Antibiotic resistance mechanism

Antioxidants food supplements

Vitamin D Details on FDA cautions on accurate dosage of Vitamin D


What is an antibody? what is monoclonal and polyclonal antibodies?

Terminologies In vaccine Production

Multi stage testing of Virus vaccine production

Testing of vaccines at different stages of production

TESTING FOR ADVENTITIOUS AGENTS CELL PROPERTIES IN VIRAL VACCINE PRODUCTION

Enzyme linked immunosorbent assay ELISA

Raido Immuno assay

http://whoguideline.blogspot.com/2010/04/terminalogy-and-their-explanations.html

Pharmaceutical Aseptic Manufacturing Process Terms , Terminology and Definitions.

http://whoguideline.blogspot.com/2010/02/pharmaceutical-aseptic-manufacturing.html

Here are some articles which will be useful for you in further understanding of aspects of sterile dosage form manufacturing and regulatory affairs and good manufacturing practice in

pharmaceutical industry

Pharmaceutical Validation

Types of validations in pharmaceutical manufacturing


Requirements of documents for validation of sterilisation process

How to investigate OOS out of specification results

Determination of Phenol coefficient of a disinfectant

Sterility testing

Clean Room Classification

Time limitations in sterile pharmaceuticals processing

Aspects of validation of manufacturing process in sterile pharmaceuticals

Clinical Trials

Requirements of US FDA Inspections of Clinical Investigators of Clinical Trials

PROCEDURE OF AN INSPECTIONS OF CLINICAL TRIAL INVESTIGATOR BY US FDA HOW ARE CLINICAL INVESTIGATOR INSPECTIONS CONDUCTED?

US FDA INSPECTION OF CLINICAL INVESTIGATORS OUT OF UNITED STATES OF AMERICA

REPORTS AFTER AN INSPECTION OF A INVESTIGAOTR OF CLINICAL TRIALS

Controlling Pyrogens in injectable dosage forms

Media fill run process simulation aspects Validation of Aseptic Process and Sterilisation

New Drug Application (NDA) how to make a New Drug Application (NDA) to US FDA

Abbreviated New Drug Application (ANDA) What is ANDA , detailed information about ANDA preparation and submission to US FDA

How to make Investigational New Drug (IND) Application to US FDA

Drug applications submission to us fda Over the counter Drugs OTC drugs

BIOAVAILABILITY AND BIOEQUIVALENCE REQUIREMENTS

Electronic record in pharmaceutical manufacturing industry

Good manufacturing practice in pharmaceutical industry

Pharmaceutical industry pharmaceutical companies and FDA latest updates